Tscan Therapeutics is trading at $0.20, with a -10.04% move amid broad pre-market weakness, though no direct stock-specific catalyst has been identified.
- No fresh company-specific announcement was identified; its investor-relations page lists October 6 as its latest release.
- S&P 500, Nasdaq Composite and Dow futures are lower, alongside weaker Asian markets and geopolitical concerns.
- The broader risk-off backdrop may help explain the decline but does not establish a direct catalyst for the stock.